E. David Crawford, MD

Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate Cancer

April 20th 2017

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.

Dr. Crawford on PSA Testing for Prostate Cancer

March 8th 2017

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.

Dr. Crawford on Ongoing Research With Radium-223 in mCRPC

July 15th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Crawford on Abiraterone Versus Enzalutamide in Prostate Cancer

March 19th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting abiraterone versus enzalutamide for the treatment of patients with castration-resistant prostate cancer.

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

January 3rd 2016

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Dr. Crawford on LHRH Agonists and GNRH Antagonists

May 16th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.

Dr. Crawford Discusses Improving Risk Stratification in Prostate Cancer With the CCP Assay

February 27th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

Dr. Crawford on Intermittent Androgen Deprivation With Degarelix

May 20th 2014

E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.

Dr. Crawford Discusses Prostate Cancer Biopsies

April 22nd 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses prostate cancer biopsies.

Dr. Crawford on Predictive Tests in Prostate Cancer

April 4th 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses valuable prognostic and predictive tests to help urologists determine when to biopsy, when to rebiopsy, and how to direct treatment for patients with a positive biopsy.

Dr. Crawford on Rebiopsying for Prostate Cancer

March 17th 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

Dr. Crawford Compares Degarelix and LHRH Agonists

September 9th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

Dr. Crawford on Sequences and Combinations in CRPC

May 20th 2013

E. David Crawford, MD, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.

Dr. Crawford on the Prostate Cancer Treatment Landscape

April 25th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the rapidly changing treatment landscape for men with advanced prostate cancer.

Dr. Crawford on Sipuleucel-T in Advanced Prostate Cancer

April 5th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.

Dr. Crawford Discusses Active Surveillance in Prostate Cancer

March 19th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Dr. Crawford on Transperineal 3D Mapping Biopsy

April 13th 2012

Dr. David Crawford, from University of Colorado Health Sciences Center, Discusses Transperineal 3D Mapping Biopsy

Dr. Crawford on Alternatives to Biopsy in Prostate Cancer

April 28th 2011

Dr. Crawford Discusses Alternatives to Biopsy in Prostate Cancer

Dr. Crawford Talks About 3D Mapping Biopsies

April 19th 2011

E. David Crawford, MD from the University of Colorado Health Sciences Center Talks About 3D Mapping Biopsies

Dr. Crawford Talks About Robotic Treatment

April 15th 2011